We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
101
Xencor
XNCR
$1.44B
$5.75M 0.22%
148,231
– –
SYNH
102
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$5.74M 0.22%
108,001
– –
FOLD
103
DELISTED
Amicus Therapeutics
FOLD
$5.73M 0.21%
405,626
+68,642
+20% +$1M
A icon
104
Agilent Technologies
A
$39.5B
$5.3M 0.2%
52,525
– –
ALLK
105
DELISTED
Allakos
ALLK
$5.25M 0.2%
64,397
– –
BCEL
106
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.92M 0.18%
352,424
– –
RVTY icon
107
Revvity
RVTY
$12.4B
$4.83M 0.18%
38,494
– –
AMED
108
DELISTED
Amedisys
AMED
$4.59M 0.17%
19,395
– –
BLUE
109
DELISTED
bluebird bio
BLUE
$4.54M 0.17%
6,500
– –
AUPH icon
110
Aurinia Pharmaceuticals
AUPH
$1.87B
$4.43M 0.17%
300,611
+209,823
+231% +$3.04M
TBPH icon
111
Theravance Biopharma
TBPH
$874M
$4.41M 0.17%
298,470
+69,634
+30% +$1.3M
NKTR icon
112
Nektar Therapeutics
NKTR
$2.38B
$4.36M 0.16%
17,539
– –
DOC icon
113
Healthpeak Properties
DOC
$14.9B
$4.08M 0.15%
150,392
– –
GBT
114
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.96M 0.15%
71,759
– –
SNN icon
115
Smith & Nephew
SNN
$12.8B
$3.89M 0.15%
99,560
– –
ACHC icon
116
Acadia Healthcare
ACHC
$2.85B
$3.87M 0.14%
131,200
– –
TAK icon
117
Takeda Pharmaceutical
TAK
$52.9B
$3.75M 0.14%
210,146
– –
CHRS icon
118
Coherus Oncology
CHRS
$222M
$3.73M 0.14%
203,103
– –
AMRN
119
Amarin Corp
AMRN
$297M
$3.58M 0.13%
42,479
– –
ABMD
120
DELISTED
Abiomed Inc
ABMD
$3.38M 0.13%
12,212
-3,582
-23% -$1.03M
BMY.RT
121
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$3.32M 0.12%
1,473,710
– –
ALGN icon
122
Align Technology
ALGN
$12.4B
$3.29M 0.12%
10,041
– –
KRTX
123
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.23M 0.12%
41,827
+11,954
+40% +$1.02M
ICPT
124
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.19M 0.12%
77,067
– –
ARWR icon
125
Arrowhead Research
ARWR
$12.1B
$3.19M 0.12%
74,186
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.